Top US Generics Players Thwarted On August At-Risk Launch Of Fingolimod
• By Aidan Fry
Leading US generics players have been hit by an injunction preventing launch of fingolimod pending trial over a dosage regimen patent • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
